miconazole (monistat) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Miconazole is a synthetic imidazole derivative, a topical antifungal agent for use in the local treatment of vaginal, and skin and nail infections due to yeasts and dermatophytes. It is particularly active against Candida spp., Trichophyton spp., Epidermophyton spp., Microsporum spp. and Pityrosporon orbiculare (Malassezia furfur), but also possesses some activity against Gram-positive bacteria. It binds to the heme moiety of the fungal cytochrome P-450 dependent enzyme lanosterol 14-alpha-demethlyase. Inhibits 14-alpha-demethlyase, blocks formation of ergosterol and leads to the buildup of toxic methylated 14-a-sterols. Miconazole also affects the synthesis of triglycerides and fatty acids and inhibits oxidative and peroxidative enzymes, increasing the amount of active oxygen species within the cell.   NCATS

Chemistry

  • SMILES: Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
  • InChIKey: BYBLEWFAAKGYCD-UHFFFAOYSA-N
  • Mol. Mass: 416.13
  • ALogP: 6.45
  • ChEMBL Molecules:
    miconazole  
    miconazole nitrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0610 - $46.2700

Australia

$5.8148 - $8.8927
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-[2-(2,4-dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1h-imidazole | 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole | acorvio | conofite | daktarin aktiv | daktarin iv | dermazole | dermonistat | dumicoat | femeron | gyno-daktarin | loramyc | micatin | miconazole | miconazole 3 | miconazole 3 combination pack | miconazole 7 | miconazole 7 combination pack | miconazole lauriad | miconazole nitrate | miconazole nitrate combination pack | miconazole oil | monistat | monistat 1 combination pack | monistat 3 | monistat-3 | monistat 3 combination pack | monistat-3 combination pack | monistat 3 combination pack (prefilled) | monistat 5 | monistat 7 | monistat 7 combination pack | monistat-derm | monistat iv (tn) | m-zole 3 combination pack | m-zole 7 dual pack | oravig | r-14889 | vusion

Organizations (52)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (7)


 

Candidiasis, Oral (approved 1973)

Candidiasis, Vulvovaginal (approved 2001)

Infections

Mycoses

Pruritus

Tinea

Tinea Pedis

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Candidiasis (Phase 4)

Candidiasis, Oral (Phase 3)

Candidiasis, Vulvovaginal (Phase 4)

Diaper Rash (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Endometriosis (Phase 1)

Health (Phase 4)

Healthy Volunteers (Phase 1)

HIV (Phase 1)

HIV Infections (Phase 3)

Intertrigo (Early Phase 1)

Melanosis (Phase 4)

Mucositis (Phase 2)

Multiple Sclerosis ()

Onychomycosis (Phase 2)

Otomycosis (Phase 3)

Stomatitis, Denture (Phase 3)

Tinea cruris (Phase 2)

Trichomonas Infections (Phase 2)

Trichomonas Vaginitis (Phase 2)

Vaginitis (Phase 3)

Vaginosis, Bacterial (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue